Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Rates are also falling more among men than among women.
A diet with the highest amounts of fiber and yogurt consumption is associated with a 33% reduced risk.
A novel drug that blocks multiple cancer-causing mutations shows promise, especially for combination therapy.
A study in mice suggests that therapies approved for breast cancer may also combat other types, including colorectal and stomach cancer.
MRTX849 shrank tumors in half of lung cancer patients with a common but difficult to target mutation.
Here’s a list of the approved drugs to treat lung cancer. Click on any of the medications for more info on dosing, side effects and d...
The investigational machine has an 85% accuracy rate.
Longer-term follow-up shows improved overall survival with Keytruda or Opdivo.
Taking low-dose aspirin is beneficial for those with head and neck cancers and lung cancers.
FDA approves Rozlytrek for cancers with certain gene mutations
First KRAS targeted therapy shows promise for lung and colon cancer
Even cancer that doesn’t affect the bones directly can contribute to bone problems.
The test was able to identify many cancers, and their location, at early stages.
The International Association for the Study of Lung Cancer made the declaration at the outset of a major cancer meeting in Barcelona.
Biomarker was not linked to response rates in two studies of Keytruda for lung cancer.
Selpercatinib shrank tumors in 68% of patients previously treated with chemotherapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.